Latham & Watkins represented Arcutis in the transaction. Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing novel innovations in immuno-dermatology, has announced that...
Arcutis Biotherapeutics’ $225 Million Non-Dilutive Debt Financing
Vaxcyte’s $100 Million Shares Offering
Latham & Watkins represented the underwriters in the transaction. Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of...
Winc’s Initial Public Offering
Latham & Watkins represented Winc, Inc. in the offering. Manatt Represents Spartan Capital Securities LLC and Revere Securities LLC. Winc, Inc., one of the fastest growing at...
Minerva Surgical’s $75 Million Initial Public Offering
Latham & Watkins represented the underwriters in the transaction. Minerva Surgical, Inc. (Minerva Surgical), a women’s health company focused on the treatment of Abnormal Uterine Bleeding (AUB),...
Neumora Therapeutics’ Collaboration With Amgen
Latham & Watkins represented Neumora in the deal. Amgen and Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering precision medicines for brain diseases, announced a strategic collaboration...
Eliem Therapeutics’ $80 Million Initial Public Offering
Latham & Watkins represented the underwriters in the offering. Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to...
Absci Corporation’s $200 Million Initial Public Offering
Goodwin Procter advised Absci, while Latham & Watkins represented the underwriters in the offering. Absci Corporation (Absci), the synthetic biology company unlocking the potential of proteins...
Lyell Immunopharma’s $425 Million Initial Pubic Offering
Latham & Watkins Advises the Underwriters in the offering while Cooley LLP represented Lyell Immunopharma. Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company...
Janux Therapeutics’ $193.8 Million IPO
Wilson Sonsini Goodrich & Rosati advised Janux Therapeutics, Inc. on the deal, while Latham & Watkins LLP represented the underwriters. Janux Therapeutics, Inc., a biopharmaceutical company...
Treace Medical Concepts’ $106.3 Million Initial Public Offering
Latham & Watkins LLP represented Treace Medical Concepts, Inc. in the offering. Treace Medical Concepts, Inc. (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a...
Rain Therapeutics’ $125 Million Initial Public Offering
Latham & Watkins LLP represented the underwriters in the offering. Rain Therapeutics Inc. (Rain), a clinical-stage company developing precision oncology therapeutics, executed its initial public offering...
Biomea’s $153 Million Initial Public Offering
Latham & Watkins LLP represented Biomea Fusion, Inc. in the transaction. Biomea Fusion, Inc. (Nasdaq: BMEA) closed its initial public offering of 9 million shares of its...